Search Results - "Porta C"

Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.

Authors: Motzer, R.J. Porta, C. Eto, M. et al.

Source: Annals of Oncology. Apr2025, Vol. 36 Issue 4, p375-386. 12p.

Valutazione del gradimento della terapia con metadone compresse rispetto allo sciroppo presso il SerDP di Fidenza.

Authors: Gariboldi, S. Pignacca, M. I. Porta, C. et al.

Source: Mission (2037-4798). dic2025, Vol. 19 Issue 72, p57-61. 5p.

This result is not displayed to guests.
Login for full access.

Biliary leak rates after cholecystectomy and intraoperative cholangiogram in surgical residency.

Authors: Shawhan, Robert R Porta, C Rees Bingham, Jason R et al.

Source: Military Medicine. May2015, Vol. 180 Issue 5, p565-569. 5p.

This result is not displayed to guests.
Login for full access.

Comparing comparators: a look at control arms in kidney cancer studies over the years.

Authors: Bracarda, S Porta, C Sisani, M et al.

Source: British Journal of Cancer. 1/6/2015, Vol. 112 Issue 1, p14-19. 6p. 3 Charts, 2 Graphs.

Sunitinib re-challenge in advanced renal-cell carcinoma.

Authors: Porta, C Paglino, C Grünwald, V

Source: British Journal of Cancer. 9/9/2014, Vol. 111 Issue 6, p1047-1053. 7p. 2 Charts, 1 Graph.

Progressive Compressively Sensed Band Processing for Hyperspectral Classification.

Authors: Della Porta, C. J. Chang, Chein-I

Source: IEEE Transactions on Geoscience & Remote Sensing. Mar2021, Vol. 59 Issue 3, p2378-2390. 13p.

Subjects: Remote sensing, Classification

Effects of creatine in a rat intestinal model of ischemia/reperfusion injury.

Authors: Orsenigo, M. Porta, C. Sironi, C. et al.

Source: European Journal of Nutrition. Apr2012, Vol. 51 Issue 3, p375-384. 10p. 2 Charts, 5 Graphs.

Detection by ELISA of Two Tobamoviruses in Orchids Using Monoclonal Antibodies.

Authors: Porta, C. Van Regenmortel, M. H. V. Dekker, E. L. et al.

Source: Journal of Phytopathology. Dec1987, Vol. 120 Issue 4, p317-326. 10p. 2 Charts, 4 Graphs.

Looking beyond search to provide effective online search tools.

Authors: Porta C (AUTHOR)

Source: Online (0146-5422). May/Jun2007, Vol. 31 Issue 3, p22-25. 4p.

URL: 24981993

N-FINDER for Finding Endmembers in Compressively Sensed Band Domain.

Authors: Bekit, Adam Chang, Chein-I Lampe, Bernard et al.

Source: IEEE Transactions on Geoscience & Remote Sensing; Feb2020, Vol. 58 Issue 2, p1087-1101, 15p

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †.

Authors: Escudier, B Porta, C Schmidinger, M et al.

Source: Annals of Oncology. May2019, Vol. 30 Issue 5, p706-720. 15p. 4 Diagrams, 8 Charts.

This result is not displayed to guests.
Login for full access.

EE190 From Clinical Trials to RWE: Defining Faricimab Value Drivers in Neovascular Age Related Macular Degeneration Through a Cost Utility Analysis.

Authors: Ghetti, G Porta, C Bührer, C et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS91-S91. 1p.

EE65 Retifanlimab vs Avelumab in Patients With Metastatic Merkel Cell Carcinoma: A Cost-Utility Analysis in Italy.

Authors: Ghetti, G Porta, C Povero, M et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS66-S66. 1p.

EE105 anti-VEGFs Use in Neovascular Age-Related Macular Degeneration: An Analysis of the National Report on Medicines Use in Italy.

Authors: Ghetti, G. Porta, C. Fasci, A.

Source: Value in Health. 2023 Supplement, Vol. 26 Issue 12, pS70-S71. 2p.

Integrated cardiovascular/respiratory control in type 1 diabetes evidences functional imbalance: Possible role of hypoxia.

Authors: Bianchi, L. Porta, C. Rinaldi, A. et al.

Source: International Journal of Cardiology. Oct2017, Vol. 244, p254-259. 6p.

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: Escudier, B. Porta, C. Schmidinger, M. et al.

Source: Annals of Oncology. 2016 Supplement, Vol. 27, pv58-v68. 11p. 1 Diagram, 8 Charts.

This result is not displayed to guests.
Login for full access.